EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Human challenge models for vaccine development—strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report

Helen R Wagstaffe, Stephanie Ascough iD, Peter J M Openshaw iD, HIC-Vac meeting contributors

Immunotherapy Advances · 30.12.2024 · 5 (1)

DOI: 10.1093/immadv/ltaf004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 08.02.2025. Verfasst von Helen R Wagstaffe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Imperial College London, London, United Kingdom. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Vaccines Research & Development, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The HIC-Vac network is a unique association of researchers focussed on the development and use of human infection challenge (HIC, otherwise known as controlled human infection models or CHIM) studies for vaccine and therapeutic development, particularly for pathogens of high global impact. The fifth annual meeting of the HIC-Vac network was held on 1–3 November 2023. The theme of the meeting was capacity-building in endemic settings particularly in low- and middle-income countries (LMIC), where pathogens cause the greatest morbidity and mortality. In this report we highlight the strengths and limitations of HIC and expansion of such studies into endemic settings, noting that immune responses and vaccine efficacy differ across diverse settings and populations. The consensus was that HIC studies must not be restricted to high income settings if they are to be relevant to LMIC populations. This report summarizes the work presented at the HIC-Vac annual meeting, highlighting current and future challenge models, challenge agent manufacture, public engagement, ethics, and industry perspectives.

Schlagwörter

Stichwörter der Autor:innen

infectious diseasevaccinevaccine development

Autor:innen und Institutionen

  • Department of Infectious Diseases, Imperial College London, London, United Kingdom.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom.

ORCID-Profile: Stephanie Ascough, Peter J M Openshaw

Förderung

  • Wellcome Trust
  • Vaccines Research & Development
  • Medical Research Council
  • Biotechnology and Biological Sciences Research Council
  • European Union

Zitieren

APA

Wagstaffe, H. R., Ascough, S., Openshaw, P. J. M., & HIC-Vac meeting contributors (2024). Human challenge models for vaccine development—strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report. Immunotherapy Advances, 5(1). https://doi.org/10.1093/immadv/ltaf004

Vancouver

Wagstaffe HR, Ascough S, Openshaw PJM, HIC-Vac meeting contributors. Human challenge models for vaccine development—strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report. Immunotherapy Advances. 2024;5(1). doi:10.1093/immadv/ltaf004

BibTeX
@article{Wagstaffe2024,
  author = {Wagstaffe, Helen R and Ascough, Stephanie and Openshaw, Peter J M and HIC-Vac meeting contributors, HIC-Vac meeting contributors},
  title = {Human challenge models for vaccine development—strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report},
  journal = {Immunotherapy Advances},
  year = {2024},
  volume = {5},
  number = {1},
  doi = {10.1093/immadv/ltaf004}
}
Kostenlos starten →